Adjuvant Therapy With Nivolumab Versus Placebo in Patients With Resected Stage IIB/C Melanoma (Checkmate 76K)

被引：0

作者：

Gastman, Brian ^{[1
]}

Long, Georgina V. ^{[2
]}

Kirkwood, John M. ^{[3
]}

Hoeller, Christoph ^{[4
,5
]}

Weber, Jeffrey ^{[6
]}

Grob, Jean-Jacques ^{[7
]}

Mohr, Peter ^{[8
]}

Grabbe, Stephan ^{[9
]}

Dutriaux, Caroline ^{[10
]}

Chiarion-Sileni, Vanna ^{[11
]}

Mackiewicz, Jacek ^{[12
]}

Rutkowski, Piotr ^{[13
]}

Arenberger, Petr ^{[14
,15
]}

Quereux, Gaelle ^{[16
]}

Meniawy, Tarek ^{[17
]}

Ascierto, Paolo A. ^{[18
]}

van Akkooi, Alexander ^{[19
,20
]}

Durani, Piyush ^{[21
]}

Campigotto, Federico ^{[21
]}

Del Vecchio, Michele ^{[22
]}

机构：

[1] Cleveland Clin Fdn, Melanoma & High Risk Skin Canc Program, Cleveland, OH USA

[2] Univ Sydney, Melanoma Inst Australia, Royal North Shore & Mater Hosp, Sydney, NSW, Australia

[3] UPMC Hillman Canc Ctr, Melanoma & Skin Canc P, Med Dermatol, Pittsburgh, PA USA

[4] Med Univ Wien, Dermatol, Vienna, Austria

[5] Med Univ Wien, Skin Canc Ctr, Vienna, Austria

[6] NYU Langone Med Ctr, Perlmutter Canc Ctr, New York, NY USA

[7] Hop La Timone, Dermatol, Marseille, France

[8] Elbe Klinikum Buxtehude, Buxtehude, Germany

[9] Univ Mainz Med Ctr, Dermatol, Mainz, Germany

[10] Hop St Andre, Bordeaux, France

[11] IRCCS, Ist Oncol Veneto, Melanoma & Esophageal Oncol Unit, San Giovanni Rotondo, Italy

[12] Poznan Univ Med Sci, Poznan, Poland

[13] Maria Sklodowska Curie Natl Res Inst Oncol, Surg Oncol, Warsaw, Poland

[14] Charles Univ Prague, Fac Med 3, Dept Dermatovenereol, Prague, Czech Republic

[15] Univ Hosp Kralovske Vinohrady, Prague, Czech Republic

[16] Nantes Univ Hosp, Nantes, France

[17] 15Sir Charles Gairdner Hosp, City Beach, WA USA

[18] Ist Nazl Tumori IRCCS Fdn G Pascale, Unit Melanoma Canc Immunotherapy & Innovat Therap, Canc Immunotherapy & Dev Therapeut Unit, Naples, Italy

[19] Univ Sydney, Melanoma Inst Australia, Fac Med & Hlth, Sydney, NSW, Australia

[20] Royal Prince Alfred Hosp, Sydney, NSW, Australia

[21] Bristol Myers Squibb, Global Oncol Clin Dev, New York, NY USA

[22] Fdn IRCCS Ist Nazl Tumori, Unit Melanoma Med Oncol, Milan, Italy

来源：

ANNALS OF SURGICAL ONCOLOGY | 2023年 / 30卷 / SUPPL 1期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S35 / S36

页数：2

共 50 条

[31] Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
Weber, J. S.
Del Vecchio, M.
Mandala, M.
Gogas, H.
Arance, A. M.
Dalle, S.
Cowey, C. L.
Schenker, M.
Grob, J. J.
Chiarion-Sileni, V.
Marquez-Rodas, I.
Butler, M. O.
Maio, M.
Middleton, M. R.
Tang, T.
Saci, A.
De Pril, V.
Lobo, M.
Larkin, J. M. G.
Ascierto, P. A.
ANNALS OF ONCOLOGY, 2019, 30 : 533 - +
[32] Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival
Weber, Jeffrey S.
Poretta, Tayla
Stwalley, Brian D.
Sakkal, Leon A.
Du, Ella X.
Wang, Travis
Chen, Yan
Wang, Yan
Betts, Keith A.
Shoushtari, Alexander N.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (04) : 955 - 955
[33] Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival
Jeffrey S. Weber
Tayla Poretta
Brian D. Stwalley
Leon A. Sakkal
Ella X. Du
Travis Wang
Yan Chen
Yan Wang
Keith A. Betts
Alexander N. Shoushtari
Cancer Immunology, Immunotherapy, 2023, 72 : 945 - 954
[34] Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
Schadendorf, Dirk
Luke, Jason John
Ascierto, Paolo A.
Long, Georgina, V
Rutkowski, Piotr
Khattak, Adnan
Del Vecchio, Michele
de la Cruz-Merino, Luis
Mackiewicz, Jacek
Sileni, Vanna Chiarion
Kirkwood, John M.
Robert, Caroline
Grob, Jean-Jacques
Dummer, Reinhard
Carlino, Matteo S.
Zhao, Yujie
Kalabis, Mizuho
Krepler, Clemens
Eggermont, Alexander
Scolyer, Richard A.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (03)
[35] NIVOLUMAB-ADJUVANT THERAPY FOR RESECTED STAGE III-IV MELANOMA: A COST-EFFECTIVENESS ANALYSIS FOR SPAIN
Presa, M.
Soria, A.
Oyaguez, I
Espinosa, E.
Echave, M.
Berrocal, A.
Manzano, J. L.
Suarez Rodriguez, J.
Polanco Sanchez, C.
VALUE IN HEALTH, 2019, 22 : S457 - S457
[36] Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design
Atkinson, Victoria G.
Hauschild, Axel
Long, Georgina V.
Mandala, Mario
Kicinski, Michal
Govaerts, Anne-Sophie
Klauck, Isabelle
Ouali, Monia
Lorigan, Paul C.
Eggermont, Alexander M. M.
van Akkooi, Alexander C. J.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 115 - 115
[37] Neoadjuvant nivolumab versus combination ipilimumab and nivolumab followed by adjuvant nivolumab in patients with resectable stage III and oligometastatic stage IV melanoma: preliminary findings
Reddy, Sangeetha M.
Amaria, Rodabe N.
Spencer, Christine N.
Tetzlaff, Michael
Reuben, Alexandre
Andrews, Miles
Wang, Linghua
Woodman, Scott
Zhu, Haifeng
Blando, Jorge
Vence, Luis
Zhang, Shaojun
Jiang, Hong
Gopalakrishnan, Vancheswaran
Hudgens, Courtney
Wani, Khalida
Tawbi, Hussein
Diab, Adi
Glitza, Isabella
Patel, Sapna
Hwu, Wen-Jen
Wong, Michael
Hwu, Patrick
Cormier, Janice
Lucci, Anthony
Royal, Richard
Lee, Jeffrey E.
Simpson, Lauren
Burton, Elizabeth M.
Gershenwald, Jeffrey E.
Ross, Merrick
Allison, James
Sharma, Padmanee
Davies, Michael
Wargo, Jennifer
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[38] Pembrolizumab versus placebo as adjuvant therapy in resected high -risk stage II melanoma: Phase 3 KEYNOTE-716 study.
Carlino, Matteo S.
Ascierto, Paolo Antonio
Eggermont, Alexander M.
Gershenwald, Jeffrey E.
Grob, Jean Jacques
Hauschild, Axel
Kirkwood, John M.
Long, Georgina V.
Mohr, Peter
Robert, Caroline
Ross, Merrick I.
Scolyer, Richard A.
Sondak, Vernon K.
Yoon, Charles
Poklepovic, Andrew Stewart
Rutkowski, Piotr
Anderson, James R.
Ahsan, Sama
Ibrahim, Nageatte
Luke, Jason J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[39] Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study
Yokota, Kenji
Uchi, Hiroshi
Uhara, Hisashi
Yoshikawa, Shusuke
Takenouchi, Tatsuya
Inozume, Takashi
Ozawa, Kentaro
Ihn, Hironobu
Fujisawa, Yasuhiro
Qureshi, Anila
de Pril, Veerle
Otsuka, Yasushi
Weber, Jeffrey
Yamazaki, Naoya
JOURNAL OF DERMATOLOGY, 2019, 46 (12): : 1197 - 1201
[40] REAL-WORLD OUTCOMES OF PATIENTS WITH RESECTED STAGE IIIA MELANOMA TREATED WITH ADJUVANT NIVOLUMAB IN A US COMMUNITY SETTING
Samlowski, Wolfram
Chan, Phillip
Pavlick, Anna
Moser, Justin
Robert, Nicholas
Poreta, Tayla
Moshyk, Andriy
Sakkal, Leon
Palaia, Jennell
Niehoff, Nicole
Rajkumar, Jonathan
Amin, Asim
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A451 - A451

← 1 2 3 4 5 →